thiophenes has been researched along with Coronary Disease in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (35.29) | 18.7374 |
| 1990's | 1 (1.96) | 18.2507 |
| 2000's | 11 (21.57) | 29.6817 |
| 2010's | 21 (41.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buse, JB; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Mellbin, L; Neal, B; Nicholls, SJ; Nozza, A; Rydén, L; Schrieks, IC; Schwartz, GG; Stähli, BE; Svensson, A; Tardif, JC; Wedel, H; Weichert, A | 1 |
| Albert, A; Rassaf, T | 1 |
| Curkovic, I; Egbring, M; Kullak-Ublick, GA | 1 |
| De Backer, G; Gill, DP; Petrella, RJ; Tremblay, G | 1 |
| Fauchère, I; Schreiber, P; Wyss, C | 1 |
| Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H | 1 |
| Collet, JP; Kerneis, M; Montalescot, G; Silvain, J | 1 |
| Allocco, DJ; Christen, T; Garratt, KN; Jenkins, RG; Kereiakes, DJ; Lee, DP; Mauri, L; Pow, TK; Weaver, WD; Winters, KJ | 2 |
| Collet, JP; Montalescot, G; Silvain, J | 1 |
| Bengus, M; Califf, R; Ditmarsch, M; Erdmann, E; Gerstein, HC; Malmberg, K; Ruilope, L; Schwartz, GG; Svensson, A; Volz, D; Wedel, H | 1 |
| Buch, AN; Shah, AH | 1 |
| Jeger, RV; Pfisterer, ME | 1 |
| Angiolillo, DJ; Bass, TA; Bates, ER | 1 |
| Brandt, JT; Braun, OO; Close, SL; Erlinge, D; James, S; Man, M; Siegbahn, A; Varenhorst, C; Walker, J; Wallentin, L; Winters, KJ | 1 |
| Dixon, SR; Grines, CL; O'Neill, WW | 1 |
| Stiefelhagen, P | 1 |
| Hamm, CW; Rassaf, T | 1 |
| Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Logan, DK; Price, MJ; Walder, JS; Winters, KJ | 1 |
| Pakhomov, IaM | 1 |
| Abtan, J; Aubry, P; Barthélémy, O; Belle, L; Beygui, F; Boueri, Z; Carrié, D; Cayla, G; Collet, JP; Cuisset, T; Elhadad, S; Henry, P; Kerneis, M; Monségu, J; Montalescot, G; Motreff, P; O'Connor, SA; Pouillot, C; Rangé, G; Rousseau, H; Sabouret, P; Saint-Etienne, C; Silvain, J; Van Belle, E; Vicaut, E | 1 |
| Bhatt, DL; Croce, KJ; Huang, PH; Resnic, FS | 1 |
| Lowry, DR; Malinin, AI; Meilman, H; Midei, MG; Serebruany, VL | 1 |
| Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Riesmeyer, J; Warmke, JW; Weerakkody, G; Winters, KJ; Wiviott, SD | 1 |
| Bliden, KP; Gurbel, PA; Tantry, US | 1 |
| Cattaneo, M | 1 |
| Angiolillo, DJ | 1 |
| Ajani, AE; Lefkovits, J | 1 |
| Alvarez, W | 1 |
| Berdeaux, PA; Giudicelli, JF | 1 |
| Fox, KM; Jonathan, A; Selwyn, AP | 1 |
| Numano, F | 1 |
| Kawai, C | 1 |
| Goebel, N; Pfluger, N; Rothlin, M; Speiser, K; Turina, M | 1 |
| Chevigné, M; David, JL; Limet, R; Rigo, P | 1 |
| Verstraete, M | 1 |
| Amin, D; Bilder, G; Bostwick, J; Byan, L; Dunwiddie, C; Galczenski, H; Kasiewski, C; Leadley, R; Ly, C; Merkel, L; Myers, M; Needle, S; O'Conner, B; Page, K; Perrone, M; Persons, P; Spada, A; Wentz, T | 1 |
| Yamashita, S | 1 |
| Hashimoto, H; Hieda, N; Ito, T; Ogawa, K; Okumura, K; Satake, T; Toki, Y | 2 |
| Harker, LA | 1 |
| Berglund, U; Wallentin, L | 1 |
| Hieda, N; Ito, T; Ogawa, K; Ogawa, T; Ozawa, T; Satake, T; Sugiyama, S; Toki, Y | 1 |
| Brown, BG; Chesebro, JH; Ekeström, S; Harker, LA; Henderson, AH; Jewitt, DE; Oliver, MF; Sleight, P; Verstraete, M | 1 |
| Bowles, MJ; Khurmi, NS; Kohli, RS; Raftery, EB | 1 |
| Imai, Y; Matsumura, H; Nishikawa, K; Terashita, Z | 1 |
| Goebel, N; Krayenbühl, HP; Pfluger, N; Rothlin, ME; Senning, A; Speiser, K; Steinbrunn, W; Turina, M | 1 |
| de Artaza, M; de Teresa, E; Lorenz, P; Marin, MC; Martín-Júdez, V; Ugarte, M | 1 |
| Avello, F; Carmona, J; Criado, A; Juffé, A; Otero, C | 1 |
14 review(s) available for thiophenes and Coronary Disease
| Article | Year |
|---|---|
[Thrombocyte aggregation inhibitors: what are the risks?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Early Medical Intervention; General Practice; Guideline Adherence; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Clinical profile of prasugrel, a novel thienopyridine.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes | 2008 |
The year in interventional cardiology.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Occlusion; Coronary Restenosis; Drug-Eluting Stents; Foramen Ovale, Patent; Hospital Mortality; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Radiology, Interventional; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
[New study findings in cardiology. The best is the enemy of the good].
Topics: Angioplasty, Balloon, Coronary; Angiotensin II Type 2 Receptor Blockers; Anticoagulants; Atrial Fibrillation; Cardiology; Coronary Disease; Drug-Eluting Stents; Heart Diseases; Humans; Morpholines; Myocardial Infarction; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2010 |
[Coronary heart disease - what is of importance after coronary intervention?].
Topics: Adenosine; Aftercare; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Drug-Eluting Stents; Gastrointestinal Hemorrhage; Humans; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Comparative antiplatelet efficacy of prasugrel and high-dose clopidogrel in patients with coronary heart disease including acute coronary syndrome].
Topics: Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation.
Topics: Adenosine; Administration, Oral; Algorithms; Coronary Disease; Elective Surgical Procedures; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Stents; Thiophenes; Ticagrelor | 2012 |
Prasugrel.
Topics: Adenosine Diphosphate; Animals; Aspirin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Collagen; Coronary Disease; Drug Evaluation, Preclinical; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2006 |
Platelet P2 receptors: old and new targets for antithrombotic drugs.
Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Interactions; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2X; Syndrome; Thiophenes; Ticagrelor; Ticlopidine | 2007 |
ADP receptor antagonism: what's in the pipeline?
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2007 |
Cyclic nucleotides, prostaglandins, and ischemic heart disease.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arteriosclerosis; Coronary Disease; Diet, Atherogenic; Myocardial Contraction; Myocardial Infarction; Nucleotides, Cyclic; Prostaglandins; Rabbits; Thiophenes; Thromboxane A2; Ticlopidine | 1984 |
[Other antihyperlipidemic drugs with novel mechanism].
Topics: Animals; Arteriosclerosis; Azetidines; Benzylamines; Carrier Proteins; CCAAT-Enhancer-Binding Proteins; Chenodeoxycholic Acid; Cholesterol; Coronary Disease; Diphosphonates; DNA-Binding Proteins; Ezetimibe; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hyperlipidemias; Hypolipidemic Agents; Lithocholic Acid; Organic Anion Transporters, Sodium-Dependent; Oxygenases; Squalene Monooxygenase; Sterol Regulatory Element Binding Protein 1; Symporters; Thiophenes; Transcription Factors | 2001 |
Antiplatelet drugs in the management of patients with thrombotic disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets; Catheterization; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Glomerulonephritis; Humans; Sulfinpyrazone; Suloctidil; Thiophenes; Thrombophlebitis; Thrombosis; Ticlopidine; Vascular Diseases; Vascular Surgical Procedures | 1986 |
15 trial(s) available for thiophenes and Coronary Disease
| Article | Year |
|---|---|
Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adiponectin; Aged; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Nonesterified; Female; Humans; Male; Middle Aged; Myocardial Infarction; Oxazoles; Retrospective Studies; Stroke; Thiophenes; Treatment Outcome | 2018 |
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Topics: Aged; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP2C19; Double-Blind Method; Elective Surgical Procedures; Female; Follow-Up Studies; Gene Frequency; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine | 2014 |
Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Incidence; Internationality; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Thiophenes; Time Factors; Treatment Outcome | 2015 |
Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
Topics: Aged; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Early Termination of Clinical Trials; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Myalgia; Myocardial Infarction; Myositis; Oxazoles; Peripheral Arterial Disease; PPAR alpha; PPAR gamma; Prediabetic State; Stroke; Thiophenes; Treatment Outcome | 2015 |
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genetic Variation; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epidemiologic; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Pyridines; Retreatment; Stents; Thiophenes; Ticlopidine | 2012 |
Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study.
Topics: Clopidogrel; Coronary Disease; Female; Flow Cytometry; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine | 2006 |
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Syndrome; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine; Treatment Outcome | 2006 |
Approaching an age of reason with antiplatelet therapy.
Topics: Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Thiophenes; Thrombosis; Ticlopidine | 2008 |
Effects of platelet inhibition on myocardial ischaemia.
Topics: Angina Pectoris; Animals; Clinical Trials as Topic; Coronary Circulation; Coronary Disease; Dogs; Double-Blind Method; Drug Evaluation, Preclinical; Female; Hemodynamics; Humans; Male; Middle Aged; Platelet Aggregation; Pyridines; Thiophenes; Ticlopidine | 1982 |
Registry of prospective clinical trials--fifth report.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Double-Blind Method; Heart Valve Prosthesis; Heparin; Humans; Intermittent Claudication; Myocardial Infarction; Prospective Studies; Registries; Thiophenes; Thromboembolism; Thrombophlebitis; Thrombosis; Ticlopidine | 1982 |
Evaluation of antiplatelet agents in the prevention of aorto-coronary bypass occlusion.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Graft Occlusion, Vascular; Heparin; Humans; Platelet Aggregation; Saphenous Vein; Sulfinpyrazone; Thiophenes; Ticlopidine | 1986 |
Does placebo improve indexes of effort-induced myocardial ischemia? An objective study in 150 patients with chronic stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Electrocardiography; Exercise Test; Female; Heart Rate; Humans; Male; Middle Aged; Physical Exertion; Placebos; Thiophenes; Ticlopidine | 1986 |
Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion.
Topics: Acenocoumarol; Anticoagulants; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Graft Occlusion, Vascular; Humans; Middle Aged; Postoperative Complications; Thiophenes; Ticlopidine | 1985 |
22 other study(ies) available for thiophenes and Coronary Disease
| Article | Year |
|---|---|
[Coronary heart disease: news about stents and bypasses].
Topics: Adenosine; Aftercare; Angioplasty, Balloon, Coronary; Coronary Disease; Follow-Up Studies; Humans; Myocardial Revascularization; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Retreatment; Risk Factors; Stents; Survival Rate; Thiophenes; Ticagrelor | 2013 |
Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey.
Topics: Acrylates; Aged; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Canada; Coronary Disease; Drug Therapy, Combination; Female; Health Care Surveys; Humans; Hypertension; Imidazoles; Male; Middle Aged; Primary Health Care; Risk Assessment; Risk Factors; Thiophenes; Time Factors; Treatment Outcome | 2014 |
New insights for low dosing with the new P2Y12 inhibitors.
Topics: Coronary Disease; Female; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes | 2014 |
Long-term secondary prevention after high-risk stenting: a good drug for a bad stent.
Topics: Aspirin; Coronary Disease; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes | 2015 |
Letter by Shah and Buch regarding article, "prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement".
Topics: Aspirin; Coronary Disease; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Piperazines; Purinergic P2Y Receptor Antagonists; Thiophenes | 2015 |
Letter by Jeger and Pfisterer regarding article, "prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement".
Topics: Aspirin; Coronary Disease; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Piperazines; Purinergic P2Y Receptor Antagonists; Thiophenes | 2015 |
Response to letters regarding article, "prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement".
Topics: Aspirin; Coronary Disease; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Piperazines; Purinergic P2Y Receptor Antagonists; Thiophenes | 2015 |
Trial watch. DAPT study.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
[Therapy of hypertension. Why the systolic value is decisive].
Topics: Acrylates; Antihypertensive Agents; Coronary Disease; Enalapril; Humans; Hypertension; Imidazoles; Risk Factors; Stroke; Systole; Thiophenes; Treatment Outcome | 2002 |
For better or for worse: the future of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine | 2008 |
[Transmural coronary blood flow redistribution in the non-ischemic and ischemic canine myocardium with S 2395, a beta-adrenoceptor blocking agent (author's transl)].
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Chromans; Coronary Circulation; Coronary Disease; Coronary Vessels; Dogs; Electrocardiography; Female; Heart; Hemodynamics; Male; Myocardium; Propanolamines; Thiophenes | 1980 |
New horizons in cardiology.
Topics: Adult; Angina, Unstable; Anticoagulants; Coronary Disease; Coronary Vessels; Electrocardiography; Female; Humans; Male; Methacrylates; Middle Aged; Myocardial Infarction; Perfusion; Stroke Volume; Thiophenes; Thromboxane A2; Thromboxane B2; Ticlopidine; Tomography, Emission-Computed; Urokinase-Type Plasminogen Activator | 1984 |
[Changes in the unmodified vessels after aortocoronary bypass surgery].
Topics: Angina Pectoris; Anticoagulants; Arterial Occlusive Diseases; Coronary Artery Bypass; Coronary Disease; Humans; Male; Middle Aged; Prospective Studies; Thiophenes; Ticlopidine | 1983 |
Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study.
Topics: Coronary Artery Bypass; Coronary Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Postoperative Complications; Radiography; Random Allocation; Saphenous Vein; Thiophenes; Ticlopidine | 1984 |
Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Coronary Disease; Enzyme Inhibitors; Protein-Tyrosine Kinases; Quinoxalines; Receptors, Platelet-Derived Growth Factor; Recurrence; Swine; Thiophenes; Time Factors; Tunica Intima; Tunica Media | 1999 |
Protective effects of a thromboxane synthetase inhibitor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart.
Topics: Animals; Arrhythmias, Cardiac; Benzoquinones; Cardiomyopathies; Chromones; Coronary Disease; Dogs; Hemorrhage; Lipoxygenase Inhibitors; Male; Myocardial Infarction; Myocardium; Neutrophils; Quinones; SRS-A; Thiophenes; Thromboxane A2; Thromboxane-A Synthase | 1989 |
Effects of ticlopidine on platelet function and on coronary insufficiency in patients with angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Blood Platelets; Coronary Disease; Humans; Male; Middle Aged; Nitroglycerin; Platelet Function Tests; Thiophenes; Ticlopidine; Time Factors | 1985 |
Myocardial salvage by a novel thromboxane A2 synthetase inhibitor in a canine coronary occlusion-reperfusion model.
Topics: Animals; Arrhythmias, Cardiac; Coronary Disease; Coronary Vessels; Dogs; Hemodynamics; In Vitro Techniques; Male; Neutrophils; Risk Factors; Thiophenes; Thromboxane A2; Thromboxane-A Synthase | 1988 |
Effect of a novel thromboxane A2 synthetase inhibitor on ischemia-induced mitochondrial dysfunction in canine hearts.
Topics: Animals; Blood Pressure; Coronary Disease; Dogs; Female; Heart Rate; In Vitro Techniques; Lysosomes; Male; Mitochondria, Heart; Oxygen Consumption; Thiophenes; Thromboxane A2; Thromboxane-A Synthase; Time Factors | 1988 |
[Antagonism of collagen-induced ECG changes in rats by a thromboxane synthetase inhibitor, CV-4151].
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Collagen; Coronary Disease; Electrocardiography; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Humans; Pyridines; Rats; Rats, Inbred Strains; Thiophenes; Thromboxane B2; Ticlopidine | 1986 |
Intracoronary platelet activation in ischemic heart disease: effects of ticlopidine.
Topics: Adult; Aged; Anticoagulants; Aorta; Blood Platelets; Coronary Disease; Coronary Vessels; Female; Humans; Male; Middle Aged; Platelet Factor 4; Thiophenes; Ticlopidine | 1985 |
Ticlopidine as a hemorrhagic risk factor in coronary surgery.
Topics: Adult; Coronary Disease; Female; Hemorrhage; Humans; Male; Platelet Aggregation; Platelet Count; Postoperative Complications; Retrospective Studies; Risk; Thiophenes; Ticlopidine | 1985 |